Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

BioLineRx (BLRX) EPS (Basic): 2012-2024

Historic EPS (Basic) for BioLineRx (BLRX) over the last 13 years, with Dec 2024 value amounting to -$0.01.

  • BioLineRx's EPS (Basic) rose 73.25% to -$0.00 in Q2 2025 from the same period last year, while for Jun 2025 it was -$0.00, marking a year-over-year increase of 89.81%. This contributed to the annual value of -$0.01 for FY2024, which is 81.60% up from last year.
  • According to the latest figures from FY2024, BioLineRx's EPS (Basic) is -$0.01, which was up 81.60% from -$0.05 recorded in FY2023.
  • BioLineRx's EPS (Basic)'s 5-year high stood at -$0.01 during FY2024, with a 5-year trough of -$0.12 in FY2020.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.03 (2022), whereas its average is -$0.03.
  • Per our database at Business Quant, BioLineRx's EPS (Basic) plummeted by 70.51% in 2023 and then soared by 81.60% in 2024.
  • BioLineRx's EPS (Basic) (Yearly) stood at -$0.12 in 2020, then spiked by 66.67% to -$0.04 in 2021, then rose by 25.00% to -$0.03 in 2022, then plummeted by 70.51% to -$0.05 in 2023, then spiked by 81.60% to -$0.01 in 2024.